Braveheart Bio, Inc.

BRVE

Insiders bought in the last twelve months.

18.71 0.84 −4.30%
Market cap
$1.8B
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Insider Decisions trades per month

Total buys 159.03
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 10 — —
Sell — — — — — — — — — — — —
Insider Ownership 70.28%

Capital & Financial Ratios $m

Market Cap 1,760.00
Revenue —
Net Income (29.75)
Free Cash Flow (22.14)
Net Debt (122.63)
Current Ratio 13.63 (at or above 1.5: strong)
Debt/Equity 0.00 (negative: negative equity)
P/E ratio —
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth —
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash — — 89 123
Receivables — — — —
Inventory — — — —
Other — — — —
— — 89 123
2023 2024 2025 Q'26
Payables — — 1 3
ST’ Debt — — — —
Other — — — —
— — 5 9

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (17) — — —
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (17) — — —
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.08) (2.51) — — —
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — — — — —

Analyst estimates 2026–2028

Powerpack
High — — — — — — — — — —
People
People Employees — — — — — — — — — 30
Revenue/emp, $m — — — — — — — — — 0.00
Income, $m
Income, $m Revenue — — — — — — — — — —
Gross margin, % — — — — — — — — — —
EBT — — — — — — — — — (66)
EBT margin, % — — — — — — — — — 0.00
Net income — — — — — — — — — (66)
Depreciation — — — — — — — — — —
Per share, $
Per share, $ Revenue — — — — — — — — — 0.00
Earnings — — — — — — — — — (17.20)
Cash flow — — — — — — — — — (0.52)
Capex — — — — — — — — — 0.00
Free cash flow — — — — — — — — — (0.52)
Book value — — — — — — — — — (17.15)
Shares, m — — — — — — — — — 4
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — — — — — — — —
P/B — — — — — — — — — —
EV/Sales — — — — — — — — — —
EV/FCF — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — — (2)
Capex — — — — — — — — — —
Free cash flow — — — — — — — — — (2)
Balance, $m
Balance, $m Working capital — — — — — — — — — 84
Total debt — — — — — — — — — —
Net debt — — — — — — — — — (89)
Shareholders’ equity — — — — — — — — — (66)
Returns, %
Returns, % ROA — — — — — — — — — 0.00
ROIC — — — — — — — — — 0.00
ROE — — — — — — — — — 0.00
Negative figures in brackets.

All 10 years →

Fundamentals updated 1 Oct 2026

Charts ten years each

Braveheart Bio, Inc. vs peers (Q) = latest quarter vs a year earlier

No peers yet.

Braveheart Bio, Inc. (BRVE) Latest News

No news at this impact. Lower the threshold for more.

stockrow.com/BRVE · Data as of Oct 1, 2026 · For information only; not investment advice. · © 2026 stockrow.com